Back to homepage

Musculoskeletal disease

Use of biologic agents and risk of tuberculosis in Brazil, a tuberculosis high-burden country

Authors: Fernanda Gomes Gonçalves Chaer MD, Juliana Miranda de Lucena Valim MD, Rogério Castro Reis MD, Giselle Burlamaqui Klautau PhD, Branca Dias Batista de Souza MSc

This study evaluated the frequency of tuberculosis infection in patients with rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, and psoriatic arthritis after the use of biologic agents in a single center of rheumatology.


Can bone turnover markers help to define the suitability and duration of bisphosphonate drug holidays?

Authors: Louise Statham MPharm, PGClin Dip, PGCHE, IPresc, Sharon Abdy RN, BSc (Hons), Terry J Aspray MBBS, MD, FRCP, FRCP(Edinburgh)

The aim of this study was to analyse changes in C-terminal telopeptide on stopping long-term blood pressures in a real-world population to see whether
persistence of BP effect was maintained.


Clinical study of the tolerability of calcium carbonate–casein microcapsules as a dietary supplement in a group of postmenopausal women

Authors: Santiago Palacios PhD, MD, Marieta Ramirez MD, Mariella Lilue MD

This article reviews the tolerability of a new delivery system for calcium supplementation, based on the functionalization of calcium carbonate (CaCO3) particles by casein proteins, in a randomized, prospective, double-blind, active comparator clinical trial.


Clinical trials: their contribution to the efficiency of the clinical management of rheumatoid arthritis

Authors: Cristina P Alcañiz Escandell MD, José A Román Ivorra PhD

This article presents a descriptive analysis of theClinical Research Unit (CRU) at the Rheumatology Department in the University and Polytechnic Hospital La Fe (RD-UPH La Fe), Valencia (Spain), as well as an estimation of the economic impact of conducting clinical trials for the Spanish Health System in terms of avoided costs.


Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis

Authors: Martina Biggioggero MD, Andrea Becciolini MD, Chiara Crotti MD, Elena Agape MD, Ennio Giulio Favalli MD

This narrative review discusses the rationale for JAK inhibition in RA, with a special focus on the role of JAK1 selective blockade and a detailed description of available data from the results of clinical trials on upadacitinib and filgotinib.